MDR - PMCF Study for Taperloc Complete Stems

This long-term follow-up study is collecting safety and outcomes data from patients who have received the Taperloc Complete hip stem — a device used in total hip replacement surgery — to confirm its safety, performance, and clinical benefits at 1, 3, 5, 7, and 10 years after implantation. Hip replacement is commonly performed for osteoarthritis, rheumatoid arthritis, fractures, and other conditions, and post-market follow-up is required to ensure ongoing device safety. Adults aged 18 or older who are skeletally mature and have undergone primary or revision hip arthroplasty with the Taperloc Complete stem for an approved indication are eligible, while those with active infection, osteoporosis, psychiatric illness, or pregnancy are excluded. Participation involves chart reviews and completion of validated patient-reported outcome questionnaires at scheduled follow-up time points. This summary was prepared to help patients understand the study in plain language.